Detailed lab analysis of Odorless Cannabis™ shows almost 600% reduction in odors


Tests were carried out at Scentroid, a laboratory specializing in the evaluation of odors and the impact of odors on the environment. At the request of one of the “big four” financial advisory firms, a report was commissioned providing extensive details on the PureScent™ technology. Specifically, a comparative analysis was conducted between the Odorless Cannabis™ product and regular cannabis with respect to the odor produced and the impact of the odor in the surrounding area. “The Odorless Cannabis™ product is revolutionary both in its quality and in the implications it has on the market,” said the President and CEO of CannabCo. Marc Pellicane. “It was important to us and our market partners that we demonstrated, quantitatively, the true impact of Odorless Cannabis™ and as such, we embraced the idea of ​​comprehensive testing by a certified laboratory.” Scentroid was chosen for its experience and extensive work with governments, municipalities, various environmental sectors and Fortune 500 companies.

Several tests were carried out under detailed and specific laboratory conditions ensuring that the products were tested under identical conditions and concentrations. “It was important to us that the repetitive results were accurate and under identical conditions to ensure the integrity and validity of the results and the final report,” said Mark NovakCOO of CannabCo.

The final test result was shocking and showed an almost 600% reduction in smell compared to regular cannabis. “We knew what to expect,” Pellicane said, “yet getting such market-relevant quantitative numbers was a big step for the company.”

The report concluded that Odorless Cannabis™ was barely detectable within a 4 meter radius, while the smell of regular cannabis was disruptive and had a negative impact within a 50 meter radius.

Scentroid also performed hedonic tests which measure the effect or likelihood of the scent having a negative impact on other people. The report states that “hedonic testing is an important measure because it means that even if the same strength odor is given off during storage, vaping or combustion, ‘odorless’ cannabis will create fewer complaints and seem less intense.” The regular smell of cannabis was found to be 90% likely to elicit a negative complaint or response, while the likelihood of generating a negative complaint or effect was insignificant with Odorless Cannabis™.

The report further states in summary that “the improvement in hedonic tone, coupled with the reduction in odor concentration, ensures that ‘odorless’ cannabis will be perceived to have significantly less odor than regular cannabis.”

In a recent press release, CannabCo announced the receipt of several mentions related to its product Odorless Cannabis™. CannabCo hails its product as a solution to the pungent smell associated with cannabis use. In an endorsement, a property manager said he would reverse the cannabis ban and allow consumption of Odorless Cannabis™ on the premises, “We would welcome the Odorless Cannabis™ product in its efforts to provide a much-needed compromise among smokers of cannabis and those tenants who have an odor problem”.

CannabCo continues to develop its products in anticipation of its industry launch in early 2022.

About CannabCo Pharmaceutical Corp.

CannabCo Pharmaceutical Corp. is a Canada-based agri-tech company with operations in Brampton, Ont.. The company has received its “confirmation of readiness” from Health Canada to become a licensed producer and is currently building its pilot facility in the Brampton area. The company currently has two main technologies, PureScent™ for the cultivation of Odorless Cannabis™, and PHOENIXan improved growing system featuring hydroponic growing technology with high productivity and significantly lower cost per gram than traditional crops.

Forward-looking statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements can be identified by statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continues”, “estimates”, “expects” and similar expressions. Actual results and developments may differ materially from those contemplated by these statements. Although CannabCo believes that the expectations reflected in the forward-looking statements in this press release are reasonable, there can be no assurance that such statements will prove to be accurate. Future events and results could differ materially from those set forth or contemplated by the forward-looking statements herein. Comments and Claims Related to PHOENIX and PURESCENT™ are based on management’s observations and opinions as well as third-party verification provided to CannabCo by industry experts.

SOURCE CannabCo Pharmaceutical Corp.

For further information: For investment information and inquiries: CannabCo Pharmaceutical Corp., [email protected];


Comments are closed.